Treatment-Related Morbidity in Prostate Cancer: A Comparison of 3-Dimensional Conformal Radiation Therapy With and Without Image Guidance Using Implanted Fiducial Markers

被引:47
作者
Singh, Jasmeet [1 ]
Greer, Peter B. [2 ]
White, Martin A. [3 ]
Parker, Joel [1 ]
Patterson, Jackie [1 ]
Tang, Colin I. [1 ,3 ]
Capp, Anne [1 ,3 ]
Wratten, Christopher [1 ,3 ]
Denham, James W. [1 ,3 ]
机构
[1] Univ Newcastle, Calvary Mater Newcastle, Newcastle, NSW 2300, Australia
[2] Univ Newcastle, Sch Phys & Math Sci, Newcastle, NSW 2300, Australia
[3] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2013年 / 85卷 / 04期
关键词
NEOADJUVANT ANDROGEN DEPRIVATION; DOSE-VOLUME CONSTRAINTS; 68; GY; RADIOTHERAPY; TRIAL; ESCALATION; TOXICITY; 3D-CRT;
D O I
10.1016/j.ijrobp.2012.07.2376
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To estimate the prevalence of rectal and urinary dysfunctional symptoms using image guided radiation therapy (IGRT) with fiducials and magnetic resonance planning for prostate cancer. Methods and Materials: During the implementation stages of IGRT between September 2008 and March 2010, 367 consecutive patients were treated with prostatic irradiation using 3-dimensional conformal radiation therapy with and without IGRT (non-IGRT). In November 2010, these men were asked to report their bowel and bladder symptoms using a postal questionnaire. The proportions of patients with moderate to severe symptoms in these groups were compared using logistic regression models adjusted for tumor and treatment characteristic variables. Results: Of the 282 respondents, the 154 selected for IGRT had higher stage tumors, received higher prescribed doses, and had larger volumes of rectum receiving high dosage than did the 128 selected for non-IGRT. The follow-up duration was 8 to 26 months. Compared with the non-IGRT group, improvement was noted in all dysfunctional rectal symptoms using IGRT. In multivariable analyses, IGRT improved rectal pain (odds ratio [OR] 0.07 [0.009-0.7], P = .02), urgency (OR 0.27 [0.11-0.63], P = <.01), diarrhea (OR 0.009 [0.02-0.35], P<.01), and change in bowel habits (OR 0.18 [0.06-0.52], P<.010). No correlation was observed between rectal symptom levels and dose-volume histogram data. Urinary dysfunctional symptoms were similar in both treatment groups. Conclusions: In comparison with men selected for non-IGRT, a significant reduction of bowel dysfunctional symptoms was confirmed in men selected for IGRT, even though they had larger volumes of rectum treated to higher doses. (C) 2013 Elsevier Inc.
引用
收藏
页码:1018 / 1023
页数:6
相关论文
共 22 条
  • [1] ROLE OF INTENSITY-MODULATED RADIOTHERAPY IN REDUCING TOXICITY IN DOSE ESCALATION FOR LOCALIZED PROSTATE CANCER
    Al-Mamgani, Abrahim
    Heemsbergen, Wilma D.
    Peeters, Stephanif T. H.
    Lebesque, Joos V.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03): : 685 - 691
  • [2] A significant decrease in rectal volume and diameter during prostate IMRT
    Anderson, Nicole S.
    Yu, James B.
    Peschel, Richard E.
    Decker, Roy H.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2011, 98 (02) : 187 - 191
  • [3] Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients
    Andreyev, Jervoise
    [J]. LANCET ONCOLOGY, 2007, 8 (11) : 1007 - 1017
  • [4] Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial
    Capp, Anne
    Inostroza-Ponta, Mario
    Bill, Dana
    Moscato, Pablo
    Lai, Chi
    Christie, David
    Lamb, David
    Turner, Sandra
    Joseph, David
    Matthews, John
    Atkinson, Chris
    North, John
    Poulsen, Michael
    Spry, Nigel A.
    Tai, Keen-Hun
    Wynne, Chris
    Duchesne, Gillian
    Steigler, Allison
    Denham, James W.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2009, 90 (03) : 400 - 407
  • [5] Delayed rectal and urinary symptomatotogy in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation
    Christie, D
    Denham, J
    Steigler, A
    Lamb, D
    Turner, S
    Mameghan, H
    Joseph, D
    Matthews, J
    Franklin, I
    Atkinson, C
    North, J
    Poulsen, M
    Spry, NA
    Tai, KH
    Wynne, C
    Duchesne, G
    Kovacev, O
    Francis, L
    Kramar, A
    D'Este, C
    Bill, D
    [J]. RADIOTHERAPY AND ONCOLOGY, 2005, 77 (02) : 117 - 125
  • [6] Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 GY)
    Cozzarini, C
    Fiorino, C
    Ceresoli, GL
    Cattaneo, GM
    Bolognesi, A
    Calandrino, R
    Villa, E
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 55 (03): : 688 - 694
  • [7] PROSTATE MOTION DURING STANDARD RADIOTHERAPY AS ASSESSED BY FIDUCIAL MARKERS
    CROOK, JM
    RAYMOND, Y
    SALHANI, D
    YANG, H
    ESCHE, B
    [J]. RADIOTHERAPY AND ONCOLOGY, 1995, 37 (01) : 35 - 42
  • [8] Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
    Dearnaley, David P.
    Sydes, Matthew R.
    Graham, John D.
    Aird, Edwin G.
    Bottomley, David
    Cowan, Richard A.
    Huddart, Robert A.
    Jose, Chakiath C.
    Matthews, John H. L.
    Millar, Jeremy
    Moore, A. Rollo
    Morgan, Rachel C.
    Russell, J. Martin
    Scrase, Christopher D.
    Stephens, Richard J.
    Syndikus, Isabel
    Parmar, Mahesh K. B.
    [J]. LANCET ONCOLOGY, 2007, 8 (06) : 475 - 487
  • [9] Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer
    Fiorino, C
    Sanguineti, G
    Cozzarini, C
    Fellin, G
    Foppiano, F
    Menegotti, L
    Piazzolla, A
    Vavassori, V
    Valdagni, R
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (04): : 953 - 962
  • [10] Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions
    Fiorino, C
    Cozzarini, C
    Vavassori, V
    Sanguineti, G
    Bianchi, C
    Cattaneo, GM
    Foppiano, F
    Magli, A
    Piazzolla, A
    [J]. RADIOTHERAPY AND ONCOLOGY, 2002, 64 (01) : 1 - 12